Secondary Immunodeficiency and Non-cystic Fibrosis Bronchiectasis.

IF 2.5 Q2 RESPIRATORY SYSTEM Tuberculosis and Respiratory Diseases Pub Date : 2024-10-01 Epub Date: 2024-08-14 DOI:10.4046/trd.2024.0015
Sungmin Zo, Ji-Yong Moon, Kyung Hoon Min, Hyun Lee
{"title":"Secondary Immunodeficiency and Non-cystic Fibrosis Bronchiectasis.","authors":"Sungmin Zo, Ji-Yong Moon, Kyung Hoon Min, Hyun Lee","doi":"10.4046/trd.2024.0015","DOIUrl":null,"url":null,"abstract":"<p><p>Bronchiectasis is a chronic respiratory disease characterized by abnormal dilation of the bronchi that causes cough, sputum, and recurrent infections. As it may be associated with various respiratory or systemic diseases, a critical aspect of managing bronchiectasis is to identify the underlying cause. Immunodeficiency is a rare but important cause of bronchiectasis, and its treatability is a significant trait for bronchiectasis management. While primary immunodeficiencies in bronchiectasis are well recognized, secondary immunodeficiencies remain under-reported and under-researched. Secondary immunodeficiencies may result from various diseases and conditions, such as hematologic malignancies, human immunodeficiency virus infection, renal transplantation, or the use of immunosuppressive drugs, and may contribute to the occurrence of bronchiectasis. Recurrent pulmonary and/or extrapulmonary infections in bronchiectasis may indicate the presence of secondary immunodeficiency in patients with these underlying conditions. For treatment, examining the underlying condition, managing bronchiectasis adequately, and prophylactic antibiotics (e.g., macrolide) and/or supplementary immunoglobulin G therapy may provide potential benefits. Considering the projected increase in the prevalence of secondary immunodeficiencies and bronchiectasis, future guidelines and research on the diagnosis and optimized treatment are needed.</p>","PeriodicalId":23368,"journal":{"name":"Tuberculosis and Respiratory Diseases","volume":null,"pages":null},"PeriodicalIF":2.5000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Tuberculosis and Respiratory Diseases","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4046/trd.2024.0015","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/8/14 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}
引用次数: 0

Abstract

Bronchiectasis is a chronic respiratory disease characterized by abnormal dilation of the bronchi that causes cough, sputum, and recurrent infections. As it may be associated with various respiratory or systemic diseases, a critical aspect of managing bronchiectasis is to identify the underlying cause. Immunodeficiency is a rare but important cause of bronchiectasis, and its treatability is a significant trait for bronchiectasis management. While primary immunodeficiencies in bronchiectasis are well recognized, secondary immunodeficiencies remain under-reported and under-researched. Secondary immunodeficiencies may result from various diseases and conditions, such as hematologic malignancies, human immunodeficiency virus infection, renal transplantation, or the use of immunosuppressive drugs, and may contribute to the occurrence of bronchiectasis. Recurrent pulmonary and/or extrapulmonary infections in bronchiectasis may indicate the presence of secondary immunodeficiency in patients with these underlying conditions. For treatment, examining the underlying condition, managing bronchiectasis adequately, and prophylactic antibiotics (e.g., macrolide) and/or supplementary immunoglobulin G therapy may provide potential benefits. Considering the projected increase in the prevalence of secondary immunodeficiencies and bronchiectasis, future guidelines and research on the diagnosis and optimized treatment are needed.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
继发性免疫缺陷和非囊性纤维化支气管扩张症。
支气管扩张症是一种慢性呼吸道疾病,其特点是支气管异常扩张,导致咳嗽、咳痰和反复感染。由于支气管扩张症可能与各种呼吸系统或全身性疾病有关,因此查明病因是治疗支气管扩张症的关键。免疫缺陷是支气管扩张症的一个罕见但重要的病因,其可治疗性是支气管扩张症治疗的一个重要特征。支气管扩张症的原发性免疫缺陷已得到广泛认可,但继发性免疫缺陷的报道和研究仍然不足。继发性免疫缺陷可能由各种疾病和病症引起,如血液系统恶性肿瘤、人类免疫缺陷病毒感染、肾移植和使用免疫抑制剂,这些都可能导致支气管扩张的发生。支气管扩张症患者反复发生肺部和/或肺外感染,可能表明这些基础疾病患者存在继发性免疫缺陷。在治疗方面,检查基础疾病、充分控制支气管扩张、预防性使用抗生素(如大环内酯类)和/或补充免疫球蛋白 G 治疗可能会带来潜在的益处。考虑到继发性免疫缺陷和支气管扩张症的发病率预计会增加,未来需要制定有关诊断和优化治疗的指南并开展相关研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
5.30
自引率
0.00%
发文量
42
审稿时长
12 weeks
期刊最新文献
Prevalence and Characteristics of Tuberculosis in the Korean Homeless Population Based on Nationwide Tuberculosis Screening. Eosinophilia Is a Favorable Marker for Pneumonia in Chronic Obstructive Pulmonary Disease. Immune Checkpoint Inhibitor Score Predicts Survival Benefit of Immunotherapy in Patients with Non-small Cell Lung Cancer. Inhaled Corticosteroids and the Risk of Nontuberculous Mycobacterial Infection in Chronic Airway Disease: A Nationwide Population-Based Study. Liberation from Mechanical Ventilation in Critically Ill Patients: Korean Society of Critical Care Medicine Clinical Practice Guidelines.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1